Patient-Level, Visit-by-Visit Data Highlight the Extent of Skin and Itch Improvement in Atopic Dermatitis With Lebrikizumab

Jonathan  Silverberg; Leon  Kircik; Melinda  Gooderham; Gaia  Gallo; Eric  Wolf; Helena  Agell; Fan Emily  Yang; Yuxin  Ding; Eric  Simpson

doi:10.25251/skin.7.supp.275

Jonathan Silverberg

The George Washington University School of Medicine and Health Sciences, Washington, DC, USA

Leon Kircik

Icahn School of Medicine at Mount Sinai, New York, USA

Melinda Gooderham

SKiN Centre for Dermatology, Peterborough, Canada

Gaia Gallo

Eli Lilly and Company, Indianapolis, USA

Eric Wolf

Eli Lilly and Company, Indianapolis, USA

Helena Agell

Almirall, S.A., Barcelona, Spain

Fan Emily Yang

Eli Lilly and Company, Indianapolis, USA

Yuxin Ding

Eli Lilly and Company, Indianapolis, USA

Eric Simpson

Oregon Health & Science University, Portland, USA

Keywords

Lebrikizumab, atopic dermatitis, itch, skin, improvement

References

1. Okragly AJ, et al. Dermatol Ther (Heidelb). 2023;13:1535-1547.

2. Silverberg JI, et al. N Engl J Med. 2023;388:1080-1091.

3. Blauvelt A, et al. Br J Dermatol. 2023;188:740-748.

4. Yosipovitch G, et al. Br J Dermatol. 2022;186:e145.

PDF

Published

Nov 13, 2023

DOI https://doi.org/10.25251/skin.7.supp.275

How to Cite

Silverberg, J. ., Kircik, L. ., Gooderham, M. ., Gallo, G. ., Wolf, E. ., Agell, H. ., Yang, F. E. ., Ding, Y. ., & Simpson, E. . (2023). Patient-Level, Visit-by-Visit Data Highlight the Extent of Skin and Itch Improvement in Atopic Dermatitis With Lebrikizumab. SKIN The Journal of Cutaneous Medicine, 7(6), s275. https://doi.org/10.25251/skin.7.supp.275

Issue

Vol. 7 No. 6 (2023): November 2023 Issue

Section

Atopic Dermatitis

This work is licensed under a Creative Commons Attribution 4.0 International License.

All authors retain copyright in their articles. All articles published open access allowing for immediate free access to the work and permitting any user to read, download, copy, distribute, print, search, or link to the full texts of articles, crawl them for indexing, pass them as data to software or use them for any other lawful purpose. Permitted reuse is defined by the following user license:

Creative Commons Attribution (CC BY): lets others distribute and copy the article, to create extracts, abstracts, and other revised versions, adaptations or derivative works of or from an article (such as a translation), to include in a collective work (such as an anthology), to text or data mine the article, even for commercial purposes, as long as they credit the author(s), do not represent the author as endorsing their adaptation of the article, and do not modify the article in such a way as to damage the author's honor or reputation.

Authors retain copyright in their work and license the publisher to publish the content. The publisher is the National Society for Cutaneous Medicine, with production and publishing support provided by OJS, Open Journal Systems,see https://pkp.sfu.ca/ojs/.

Prior to January 2022, authors transferred copyright to the National Society for Cutaneous Medicine. However, all articles are freely available to anyone in the world. There are no subscription fees, page charges, or article processing charges.

Most read articles by the same author(s)

Richard Warren , April Armstrong , Melinda Gooderham, Bruce Strober , Diamant Thaci, Shinichi Imafuku, Howard Sofen, Lynda Spelman, Neil Korman, Min Zheng, Elizabeth Colston, John Throup , Sundeep Kundu, Renata Kisa, Subhashis Banerjee, Andrew Blauvelt, Deucravacitinib, an Oral, Selective Tyrosine Kinase 2 (TYK2) Inhibitor, in Moderate to Severe Plaque Psoriasis: 52-Week Efficacy Results From the Phase 3 POETYK PSO-1 and PSO-2 Trials , SKIN The Journal of Cutaneous Medicine: Vol. 6 No. 2 (2022): March Issue and Poster Presentations (FC PANP 21 and WC 22 Dermatology Conferences®)
Amy Paller, Andrew Blauvelt, Weily Soong, Shinichi Imafuku, Chih-ho Hong, Marie Schuttelaar, Petra Amoudruz, Azra Kurbasic, Lise Soldbro, Katja Lophaven, Michael Cork, Anthony Bewley, Eric Simpson, Efficacy and safety of tralokinumab in adolescents with moderate-to- severe atopic dermatitis: results of the phase 3 ECZTRA 6 trial , SKIN The Journal of Cutaneous Medicine: Vol. 6 No. 2 (2022): March Issue and Poster Presentations (FC PANP 21 and WC 22 Dermatology Conferences®)
Diamant Thaci, Kenneth Gordon , Melinda Gooderham, Bruce Strober , Neil Korman, Subhashis Banerjee, Subhashis Banerjee, Elizabeth Colston, Jonghyeon Kim, John Throup, Akimichi Morita, Deucravacitinib, an Oral, Selective Tyrosine Kinase 2 (TYK2) Inhibitor, Compared With Placebo and Apremilast in Moderate to Severe Psoriasis: Integrated Laboratory Parameter Results From the Phase 3 POETYK PSO-1 and POETYK PSO-2 Trials , SKIN The Journal of Cutaneous Medicine: Vol. 5 No. 6 (2021): November Issue & Poster Presentations (FC21 Dermatology Conference®)
Mark Lebwohl, Linda Stein Gold, Bruce Strober, April Armstrong, H Chih-Ho Hong, Leon Kircik, Jennifer Soung, Jeff Fromowitz, Scott Guenthner, Stephen Piscitelli, David Rubenstein, Philip Brown, Anna Tallman, Robert Bissonnette, Tapinarof Cream 1% QD for the Treatment of Plaque Psoriasis: Efficacy and Safety in Two Pivotal Phase 3 Trials , SKIN The Journal of Cutaneous Medicine: Vol. 4 No. 6 (2020): November Issue & Poster Presentations (FC20 Dermatology Conference®)
Todd Schlesinger, Leon Kircik, James Del Rosso, Darrell Rigel, Mark Lebwohl, Brian Berman, April Armstrong, Neal Bhatia, Vishal A. Patel, Siva Narayanan, Volker Koscielny, Ismail Kasujee, Clinician- and Patient-Reported Outcomes with Tirbanibulin 1% Treatment for Actinic Keratosis in Routine Clinical Practice Across the U.S. (PROAK Study) , SKIN The Journal of Cutaneous Medicine: Vol. 7 No. 3 (2023): May Issue and Posters from WCH23 & WCM23
Graham H Litchman DO, MS, Quinn Thibodeaux, Ryan Rivera-Oyola, John Koo, Rick Fried, Gary Goldenberg, George Han, Sylvia Hsu, Leon Kircik, Melissa Knuckles, Andrea Murina, Jashin Wu, Mark Lebwohl, Should Package Insert Warnings Deter Prescribing in Psoriasis Patients with Depression? , SKIN The Journal of Cutaneous Medicine: Vol. 5 No. 1 (2021): January Issue & Poster Presentations (WC21 Dermatology Conference®)
Mark Lebwohl, Leon Kircik, Angela Moore, Linda Stein Gold, James Del Rosso, Zoe Draelos, Melinda Gooderham, Lawrence Green, Adelaide Herbert, Kim Papp, Jerry Bagel, Neal Bhatia, Laura Ferris, Terry Jones, Steve Kempers, David Pariser, Paul Yamauchi, Matthew Zirwas, Amy Feng, Patrick Burnett, Robert Higham, David Berk, Once-Daily Roflumilast Cream 0.3%, a Potent Phosphodiesterase-4 Inhibitor, Provided Safe and Effective Treatment of Psoriasis in the DERMIS-1 and DERMIS-2 Phase 3 Trials , SKIN The Journal of Cutaneous Medicine: Vol. 5 No. 6 (2021): November Issue & Poster Presentations (FC21 Dermatology Conference®)
Kim Papp, Jacek C. Szepietowski, Leon Kircik, Darryl Toth, Michael E. Kuligowski, May E. Venturanza, Kang Sun, Eric L. Simpson, Efficacy and Safety of Ruxolitinib Cream for the Treatment of Atopic Dermatitis: Results From Two Phase 3, Randomized, Double-Blind Studies , SKIN The Journal of Cutaneous Medicine: Vol. 4 No. 6 (2020): November Issue & Poster Presentations (FC20 Dermatology Conference®)
Linda Stein Gold, Mark Lebwohl, Kim Papp, Melinda Gooderham, Leon Kircik, Zoe Draelos, Steven Kempers, David Pariser, Javier Alonso-Llamazares, Darryl Toth, Kathleen Smith, Robert Higham, Lynn Navale, Howard Welgus, David Berk, Roflumilast Cream (ARQ-151) Improved Itch Severity and Itch-Related Sleep Loss in Adults With Chronic Plaque Psoriasis in a Phase 2b Study , SKIN The Journal of Cutaneous Medicine: Vol. 4 No. 6 (2020): November Issue & Poster Presentations (FC20 Dermatology Conference®)
Leon Kircik, Mark Lebwohl, Kim Papp, Melinda Gooderham, Linda Stein Gold, Zoe Draelos, Steven Kempers, Stephen Tyring, Lorne Albrecht, Marni Wiseman, Laura Ferris, Kathleen Smith, Robert Higham, Lynn Navale, Howard Welgus, David Berk, Roflumilast Cream (ARQ-151) 0.15% and 0.3% Improved Burden of Signs and Symptoms in Adults With Chronic Plaque Psoriasis in a Phase 2b Study , SKIN The Journal of Cutaneous Medicine: Vol. 4 No. 6 (2020): November Issue & Poster Presentations (FC20 Dermatology Conference®)

1 2 3 4 5 6 7 8 9 10 > >>

Main Article Content

Keywords

References

Article Sidebar

Article Details

Most read articles by the same author(s)